UC-MSC Therapy for Diabetes
Patient-Focused Regenerative Support at La Vida
At La Vida Stem Cells, we offer an advanced, investigational regenerative approach for individuals living with diabetes using fresh, never-frozen umbilical cord–derived mesenchymal stem cells (UC-MSCs). These cells are studied worldwide for their ability to reduce inflammation, support immune balance, and promote cellular repair.
This therapy is designed to support your body’s natural healing processes and is not a cure or a replacement for insulin or standard diabetes care.
How UC-MSCs May Help
- Reduce harmful inflammation linked to insulin resistance
- Support immune balance (especially in autoimmune-driven diabetes)
- Promote healthier pancreatic cellular signaling
- Support circulation and tissue repair affected by diabetes
Type 1 & Type 2 Diabetes (Investigational Use)
Type 1 Diabetes: Studied for immune modulation and support of remaining beta-cell function.
Type 2 Diabetes: Studied for improving insulin sensitivity and reducing metabolic inflammation.
Some patients in published studies have reported improved glucose stability and reduced medication requirements; however, individual results vary.
La Vida Dosing Strategy
350 Million UC-MSCs:
- Designed for systemic anti-inflammatory and immune-modulating support
- Often appropriate for moderate disease burden or earlier intervention
700 Million UC-MSCs:
- Designed for advanced metabolic dysfunction or long-standing diabetes
- Provides greater systemic reach and regenerative signaling
Final dosing recommendations are determined by our medical team following a comprehensive clinical review.
Treatment Delivery
UC-MSCs are typically administered via intravenous (IV) infusion, allowing regenerative signaling factors to circulate systemically throughout the body.
Diabetes FAQ
Is UC-MSC therapy a cure for diabetes?
No. UC-MSC therapy is investigational and is not a cure. It is designed to complement standard medical care.
Can this replace insulin or medications?
No. Patients should continue all prescribed medications unless advised otherwise by their physician.
Who may be a candidate?
Patients with Type 1 or Type 2 diabetes seeking investigational regenerative support under medical supervision.
How long do results last?
Results vary. Some patients report benefits lasting months, while others may require repeat therapy.
Is this FDA approved?
No. UC-MSC therapy for diabetes is not FDA-approved and is considered investigational.
Is the clinical assessment free?
Yes. The initial clinical assessment is complimentary and provided at no cost.
Important Medical Disclosure
UC-MSC therapy for diabetes is investigational and not FDA-approved to treat or cure diabetes. Results are not guaranteed and vary by individual. This therapy is intended to complement—not replace—standard medical care.
